Is Surgery Partners’ (SGRY) Q1 Beat And Reaffirmed 2026 Outlook Altering The Investment Case?

Surgery Partners, Inc. reported past first-quarter 2026 results with revenue of US$810.9 million, a narrower net loss of US$35.9 million, and reaffirmed full-year 2026 revenue guidance of US$3.35 billion to US$3.45 billion alongside at least US$530 million in adjusted EBITDA. The company’s 4.4% same-facility revenue growth and significant earnings beat versus analyst expectations highlighted solid operating execution and underlying demand strength at its centers. We’ll now examine how reaffirmed full-year guidance, underpinned by same-facility revenue growth, may influence Surgery Partners’ existing investment narrative.

AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Surgery Partners Investment Narrative Recap

To own Surgery Partners, you need to believe that outpatient surgery will keep taking share from hospitals and that the company can translate growing case volumes into sustainable profitability despite its debt load. The reaffirmed 2026 guidance, backed by 4.4% same-facility revenue growth, supports the near term catalyst of hitting revenue and EBITDA targets, but it does not remove the key risk around execution on portfolio optimization and the impact of higher interest costs on already negative earnings.

The most relevant recent development here is management’s decision to reaffirm full year 2026 guidance of US$3.35 billion to US$3.45 billion in revenue and at least US$530 million of adjusted EBITDA. That stance, following a quarter of modest revenue growth and a narrower loss, ties directly into the short term catalyst: proving that Surgery Partners can grow same facility revenue while managing costs, even as it pursues asset sales and other portfolio moves that could affect margins and leverage.

But while guidance looks intact for now, investors should be aware that the real test will come if portfolio optimization starts to pressure margins and cash flow...

Read the full narrative on Surgery Partners (it's free!)

Surgery Partners' narrative projects $3.9 billion revenue and $45.5 million earnings by 2029.

Uncover how Surgery Partners' forecasts yield a $18.80 fair value, a 31% upside to its current price.

Exploring Other PerspectivesSGRY 1-Year Stock Price Chart

Some analysts were already far more optimistic, assuming revenue could reach about US$4.2 billion and earnings about US$53.8 million, yet the latest guidance and interest cost pressures may cause both bullish and cautious views to shift as new results come through.

Story Continues

Explore 2 other fair value estimates on Surgery Partners - why the stock might be worth just $18.80!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

A great starting point for your Surgery Partners research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Our free Surgery Partners research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Surgery Partners' overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them. Uncover the next big thing with 25 elite penny stocks that balance risk and reward. The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SGRY.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments